Spain
Spain Psychedelic Therapeutics Market Industry Trends and Forecast to 2034: Segmented by (Compound, Indication, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Spain · 2024–2034 · estimates
Values shown here are estimates. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.
Germany at $120.6 Mn.
Russia at 13% a year.Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.
$124.7 Mn total, 2026–2034
| Year | Market size | Change that year | Since 2025 |
|---|---|---|---|
| 2024 (estimate) | $60.3 Mn | — | — |
| 2025 (base) | $67.7 Mn | +$7.4 Mn | — |
| 2026 (forecast) | $76.1 Mn | +$8.3 Mn | +12.3% |
| 2027 (forecast) | $85.4 Mn | +$9.4 Mn | +26.1% |
| 2028 (forecast) | $95.9 Mn | +$10.5 Mn | +41.6% |
| 2029 (forecast) | $107.7 Mn | +$11.8 Mn | +59% |
| 2030 (forecast) | $121.0 Mn | +$13.2 Mn | +78.6% |
| 2031 (forecast) | $135.8 Mn | +$14.9 Mn | +100.6% |
| 2032 (forecast) | $152.5 Mn | +$16.7 Mn | +125.2% |
| 2033 (forecast) | $171.3 Mn | +$18.8 Mn | +153% |
| 2034 (forecast) | $192.4 Mn | +$21.1 Mn | +184.1% |
Estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.
US
$1.55 Bn
China
$325.4 Mn
Canada
$276.7 Mn
Japan
$237.6 Mn
Germany
$120.6 Mn
UK
$109.5 Mn
France
$108.8 Mn
Italy
$101.7 Mn
Brazil
$88.9 Mn
Ecuador
$78.0 Mn
India
$80.7 Mn
Saudi Arabia
$71.7 Mn
Spain (this report)
$67.7 Mn
Mexico
$65.2 Mn
Australia
$45.3 Mn
New Zealand
$42.8 Mn
Russia
$33.5 Mn
South Africa
$24.5 Mn
UAE
$18.5 Mn
Egypt
$9.8 Mn
Philippines
$8.0 Mn
Hong Kong
$6.3 Mn
Malaysia
$5.4 Mn
Thailand
$5.3 Mn
Singapore
$5.0 Mn
Kenya
$2.5 Mn
Psychedelic therapeutics use compounds such as psilocybin, MDMA and LSD with therapy support to treat depression, PTSD and addiction.
Key segments of the psychedelic Therapeutics market include compound (Psilocybin, MDMA and LSD) and indication (Treatment-Resistant Depression, PTSD and Substance Use Disorder).
More people seeking help for mental health, less stigma, better screening and new treatments with faster effects are driving the psychedelic Therapeutics market. Governments and employers are investing more in mental health care.
Digital tools, new drug classes and care built into primary care and workplaces give the psychedelic Therapeutics market strong room to grow worldwide.
Shortages of mental health professionals, limited insurance coverage, side effects and the need for long-term treatment hold back the psychedelic Therapeutics market.
The psychedelic Therapeutics market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for psychedelic Therapeutics. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Spain.
What doctors and scientists are doing in Psychedelic Therapeutics right now, from free public sources.
Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
From our blog
Spain
Spain
Spain
Spain
Spain
Spain
OTC & Nutraceuticals · Spain
Digital Health · Spain
Digital Health · Spain
OTC & Nutraceuticals · Spain
Healthcare Services · Spain
Healthcare Services · Spain